Ones To Watch News
Refine search
Biotechnology
Cambridge, UK-based Alchemab Therapeutics has appointed Ulrich Wendt as chief business officer (CBO) to expand partnerships with biopharma for the development of novel antibody therapeutics 17 March 2026
Biotechnology
UK biotech Mestag Therapeutics has secured $40 million to fund its first clinical study, as it advances a fibroblast-targeted immunotherapy into human testing. 17 March 2026
Pharmaceutical
Days after announcing an exclusive licensing and supply agreement with South Korean pharma company Ahngook Pharmaceutical, George Medicines has announced another deal relating to GMRx2. 16 March 2026
Pharmaceutical
Young British biotech Ternary Therapeutics has raised £3.6 million ($4.6 million) in seed funding to advance an artificial intelligence platform designed to create “molecular glue” drugs, compounds that force two proteins inside cells to bind together and alter disease-driving biology. 16 March 2026
Biotechnology
California, USA based biotech Unnatural Products, which is developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced the closing of a $45 million Series B financing. 16 March 2026
Biotechnology
Swiss biotech Idorsia said chief executive Srishti Gupta has stepped down from her role and from the company’s board, less than a year after taking the helm. Founder and chairman Jean-Paul Clozel will take charge of day-to-day operations as interim CEO while the board searches for a permanent successor. 16 March 2026
Biotechnology
Israeli clinical-stage drug developer Purple Biotech today announced that its chief executive, Gil Efron, will step down from his role as CEO effective August 2026. 13 March 2026
Pharmaceutical
Chinese radiopharmaceutical startup Eli Radiopharma has secured around 100 million yuan ($14.5 million) in fresh financing as it expands its pipeline and deepens industry partnerships. The Hangzhou-based company said the funds will support target discovery, platform development and clinical translation across oncology and neurological disease programs. 13 March 2026
Biotechnology
US biotech Regenxbio has announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, its gene therapy for Duchenne muscular dystrophy (DMD). 13 March 2026
Biotechnology
This week on The Pharma Letter Podcast, we’re joined by Eron Kelly, chief executive of ConcertAI: a company applying artificial intelligence to accelerate oncology research and clinical development. 13 March 2026
Pharmaceutical
Ratio Therapeutics, a US pharma company developing radiopharmaceuticals for cancer treatment and monitoring, has announced the appointment of Colin Hayward as chief medical officer (CMO). 13 March 2026
Pharmaceutical
Swiss neurotechnology firm MindMaze Therapeutics has appointed healthtech executive Zach Henderson as chief executive, as the company looks to expand adoption of its FDA-cleared neurorestorative platform in the USA. 12 March 2026
Pharmaceutical
US biotech Vima Therapeutics has secured $40 million in a series A extension to support development of its oral movement-disorder therapy VIM0423, bringing the total financing round to $100 million. The funding was led by Frazier Life Sciences and includes participation from existing investors Atlas Venture, Access Industries and Canaan Partners. 12 March 2026
Biotechnology
Cambridge, UK based 4basebio, a specialist in synthetic DNA manufacturing, today announced the appointment of Scott Lorimer as chief operating officer (COO), effective immediately. 12 March 2026
Biotechnology
TolerogenixX, a biopharma developing personalized cell therapies to induce sustained immune tolerance in organ transplantation and autoimmune diseases, has achieved an important milestone with its lead cell therapy candidate, MIC-Lx. 11 March 2026
Pharmaceutical
UK-based cardiometabolic disease specialist George Medicines has entered into an exclusive licensing and supply agreement with South Korean pharma company Ahngook Pharmaceutical. 11 March 2026
Biotechnology
Danish biotech Commit Biologics has appointed Thomas Andresen as chief executive officer as the company prepares to move its complement-based immunotherapy platform toward the clinic. 11 March 2026
Pharmaceutical
China’s Ascletis Pharma has announced positive top-line results from a US Phase II, 24-week study for its subcutaneous (SC) depot formulations of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for obesity. 11 March 2026
Biotechnology
US clinical-stage ophthalmics company Qlaris Bio has appointed Fred Guerard as president and chief executive officer (CEO), effective March 1, 2026. He will also join the company’s board of directors. 11 March 2026
Biotechnology
The recent news flow at Dewpoint Therapeutics—the firm making condensate biology a clinical reality—has been striking in its volume and significance. 10 March 2026
Biotechnology
Cambridge, UK-based Alchemab Therapeutics has appointed Ulrich Wendt as chief business officer (CBO) to expand partnerships with biopharma for the development of novel antibody therapeutics 17 March 2026
Biotechnology
UK biotech Mestag Therapeutics has secured $40 million to fund its first clinical study, as it advances a fibroblast-targeted immunotherapy into human testing. 17 March 2026
Pharmaceutical
Days after announcing an exclusive licensing and supply agreement with South Korean pharma company Ahngook Pharmaceutical, George Medicines has announced another deal relating to GMRx2. 16 March 2026
Pharmaceutical
Young British biotech Ternary Therapeutics has raised £3.6 million ($4.6 million) in seed funding to advance an artificial intelligence platform designed to create “molecular glue” drugs, compounds that force two proteins inside cells to bind together and alter disease-driving biology. 16 March 2026
Biotechnology
California, USA based biotech Unnatural Products, which is developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced the closing of a $45 million Series B financing. 16 March 2026
Biotechnology
Swiss biotech Idorsia said chief executive Srishti Gupta has stepped down from her role and from the company’s board, less than a year after taking the helm. Founder and chairman Jean-Paul Clozel will take charge of day-to-day operations as interim CEO while the board searches for a permanent successor. 16 March 2026
Biotechnology
Israeli clinical-stage drug developer Purple Biotech today announced that its chief executive, Gil Efron, will step down from his role as CEO effective August 2026. 13 March 2026
Pharmaceutical
Chinese radiopharmaceutical startup Eli Radiopharma has secured around 100 million yuan ($14.5 million) in fresh financing as it expands its pipeline and deepens industry partnerships. The Hangzhou-based company said the funds will support target discovery, platform development and clinical translation across oncology and neurological disease programs. 13 March 2026
Biotechnology
US biotech Regenxbio has announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, its gene therapy for Duchenne muscular dystrophy (DMD). 13 March 2026
Biotechnology
This week on The Pharma Letter Podcast, we’re joined by Eron Kelly, chief executive of ConcertAI: a company applying artificial intelligence to accelerate oncology research and clinical development. 13 March 2026
Pharmaceutical
Ratio Therapeutics, a US pharma company developing radiopharmaceuticals for cancer treatment and monitoring, has announced the appointment of Colin Hayward as chief medical officer (CMO). 13 March 2026
Pharmaceutical
Swiss neurotechnology firm MindMaze Therapeutics has appointed healthtech executive Zach Henderson as chief executive, as the company looks to expand adoption of its FDA-cleared neurorestorative platform in the USA. 12 March 2026
Pharmaceutical
US biotech Vima Therapeutics has secured $40 million in a series A extension to support development of its oral movement-disorder therapy VIM0423, bringing the total financing round to $100 million. The funding was led by Frazier Life Sciences and includes participation from existing investors Atlas Venture, Access Industries and Canaan Partners. 12 March 2026
Biotechnology
Cambridge, UK based 4basebio, a specialist in synthetic DNA manufacturing, today announced the appointment of Scott Lorimer as chief operating officer (COO), effective immediately. 12 March 2026
Biotechnology
TolerogenixX, a biopharma developing personalized cell therapies to induce sustained immune tolerance in organ transplantation and autoimmune diseases, has achieved an important milestone with its lead cell therapy candidate, MIC-Lx. 11 March 2026
Pharmaceutical
UK-based cardiometabolic disease specialist George Medicines has entered into an exclusive licensing and supply agreement with South Korean pharma company Ahngook Pharmaceutical. 11 March 2026
Biotechnology
Danish biotech Commit Biologics has appointed Thomas Andresen as chief executive officer as the company prepares to move its complement-based immunotherapy platform toward the clinic. 11 March 2026
Pharmaceutical
China’s Ascletis Pharma has announced positive top-line results from a US Phase II, 24-week study for its subcutaneous (SC) depot formulations of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for obesity. 11 March 2026
Biotechnology
US clinical-stage ophthalmics company Qlaris Bio has appointed Fred Guerard as president and chief executive officer (CEO), effective March 1, 2026. He will also join the company’s board of directors. 11 March 2026
Biotechnology
The recent news flow at Dewpoint Therapeutics—the firm making condensate biology a clinical reality—has been striking in its volume and significance. 10 March 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze